BIO-11006(BIO-11006) - 药物靶点：MARCKS_专利_临床

概要

基本信息

药物类型

合成多肽

别名

靶点

MARCKS

作用机制

MARCKS抑制剂(豆蔻酰化富丙氨酸C 激酶底物蛋白抑制剂)

治疗领域

肿瘤呼吸系统疾病其他疾病

在研适应症-

非在研适应症

晚期非小细胞肺癌炎症非小细胞肺癌IIIB期+ [2]

原研机构

BioMarck Pharmaceuticals Ltd.

在研机构-

非在研机构

BioMarck Pharmaceuticals Ltd.

最高研发阶段无进展临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

结构

分子式C46H75N13O15

InChIKeyKCSNGWMKFYVMKF-HGYIIGRXSA-N

CAS号901117-03-1

序列信息

Sequence Code 59919

关联

5

项与 BIO-11006 相关的临床试验

NCT04183062 / Active, not recruiting临床2期IIT

A Phase 2 Study of the Safety and Efficacy of BIO-11006 in the Treatment of Recurrent Osteosarcoma and Ewing's Sarcoma in Patients With Lung Metastases

This is a Phase 2 study of an investigational drug, BIO-11006, for the treatment of lung metastases in pediatric patients with advanced osteosarcoma or Ewing's sarcoma. This study will enroll up to 10 patients aged between 5 and 21 at Nicklaus Children's Hospital in Miami, FL. Patients will receive BIO-11006 in addition to chemotherapy consisting of gemcitabine and docetaxel. This study will test the hypothesis that BIO-11006 will enhance the effect of the gemcitabine and docetaxel chemotherapy to treat lung metastases in osteosarcoma and Ewing's sarcoma.

开始日期2019-10-04

申办/合作机构

Nicklaus Children's Hospital

NCT03472053 / Completed临床2期

A Randomized Study of the Safety and Efficacy of BIO-11006 in Treatment of Advanced Non-Small Cell Lung Cancer in Patients Who Are Not Candidates for Curative Surgery and/or Radiation and Who Are Receiving Pemetrexed and Carboplatin

This Phase 2 is a randomized study in advanced Non-Small Cell lung cancer patients to evaluate safety and efficacy of aerosolized BIO-11006 in conjunction with chemotherapy.

开始日期2018-02-01

申办/合作机构

BioMarck Pharmaceuticals Ltd.

CTRI/2018/01/011152 / Completed临床2期

A Randomized Study of the Safety and Efficacy of BIO-11006 in the Treatment of Advanced Nonâ??Small Cell Lung Cancer in Patients who Are not Candidates for Curative Surgery and/or Radiation and who Are Receiving Pemetrexed and Carboplatin.

开始日期2018-01-12

申办/合作机构

BioMarck Pharmaceuticals Ltd.

100 项与 BIO-11006 相关的临床结果

登录后查看更多信息

100 项与 BIO-11006 相关的转化医学

登录后查看更多信息

100 项与 BIO-11006 相关的专利（医药）

登录后查看更多信息

5

项与 BIO-11006 相关的文献（医药）

2022-04-01·Journal of Ocular Pharmacology and Therapeutics4区 · 医学

Peptide Inhibitors of MARCKS Suppress Endotoxin Induced Uveitis in Rats

4区 · 医学

Article

作者: Stonex, Tara ; Gilger, Brian C. ; Adler, Kenneth B. ; Salmon, Jacklyn H.

Purpose: To determine if inhibition of Myristoylated Alanine Rich C Kinase Substrate (MARCKS) protein, using novel MARCKS inhibitor peptides, will reduce the severity of endotoxin-induced uveitis (EIU) in rats. Methods: EIU was induced in Lewis rats using subcutaneous administration of lipopolysaccharide. In the first phase of the study, 3 different novel MARCKS inhibitor peptides that mimic the N-terminal region of MARCKS (BIO-11006, or lower molecular weight analogs BIO-91201 or BIO-91202; Biomarck Pharmaceuticals, Ltd., Newtown, PA) were administered intravitreally (IVT) at 50 and 100 μM. In the second phase, BIO-91201 was administered IVT at 10, 50, and 100 μM and topically at the 100 μM concentration. The efficacy of MARCKS inhibitor peptides was assessed by clinical examination using slit lamp biomicroscopy, optical coherence tomography (OCT) anterior chamber cell counts, histopathology, and aqueous humor cytokine analysis. Results: Clinical scores were significantly reduced 24 h following uveitis induction in the first phase of the study in the following treatment groups: BIO-11006 50 μM IVT and 100 μM IVT, BIO-91201 50 μM IVT, and BIO-91202 100 μM IVT (P < 0.05). OCT anterior chamber cell counts were significantly reduced in the first phase of the study in all treatment groups (P < 0.001). OCT anterior chamber cell counts and histopathology scores were significantly reduced in the second phase of the study in the BIO-91201 50 μM IVT group (P < 0.05). No effect was seen with topical administration. Conclusion: MARCKS inhibitor peptides were effective in reducing the severity of ocular inflammation and cellular influx in EIU.

2016-11-01·American Journal of Respiratory Cell and Molecular Biology1区 · 医学

An Inhaled Inhibitor of Myristoylated Alanine-Rich C Kinase Substrate Reverses LPS-Induced Acute Lung Injury in Mice

1区 · 医学

Article

作者: Parikh, Indu ; Yin, Qi ; Park, Joungjoa ; Crews, Anne L. ; Fang, Shijing ; Adler, Kenneth B.

Intratracheal instillation of bacterial LPS is a well-established model of acute lung injury (ALI) and/or acute respiratory distress syndrome (ARDS). Because the myristoylated alanine-rich C kinase substrate (MARCKS) protein is involved in neutrophil migration and proinflammatory cytokine production, we examined whether an aerosolized peptide that inhibits MARCKS function could attenuate LPS-induced lung injury in mice. The peptide, BIO-11006, was delivered at 50 μM via inhalation either just before intratracheal instillation of 5 μg of LPS into Balb/C mice, or 4, 12, 24, or 36 hours after LPS instillation. Effects of BIO-11006 were evaluated via analysis of mouse disease-related behavior, lung histology, bronchoalveolar lavage fluid total protein, neutrophil counts and percentages, cytokine (KC [CXCl1, mouse IL-8 equivalent] and TNF-α) expression, and activation of NF-κB in lung tissue. Treatment with aerosolized BIO-11006 at 0, 4, 12, 24, and even 36 hours after LPS instillation reversed the disease process: mouse behavior returned to normal after two treatments 12 hours apart with the inhaled peptide after LPS injury, whereas control LPS-instilled animals treated with PBS only remained moribund. Histological appearance of inflammation, bronchoalveolar lavage fluid protein levels, leukocyte and neutrophil numbers, KC and TNF-α gene and protein expression, and NF-κB activation were all significantly attenuated by inhaled BIO-11006 at all time points. These results implicate MARCKS protein in the pathogenesis of ALI/ARDS and suggest that MARCKS-inhibitory peptide(s), delivered by inhalation, could represent a new and potent therapeutic treatment for ALI/ARDS, even if administered well after the disease process has begun.

2016-01-01·Pharmacology4区 · 医学

Novel Therapies to Inhibit Mucus Synthesis and Secretion in Airway Hypersecretory Diseases

4区 · 医学

Review

作者: Ha, Emily V. S. ; Rogers, Duncan F.

Background: In asthma and chronic obstructive pulmonary disease (COPD), airway mucus hypersecretion contributes to impaired mucociliary clearance, mucostasis and, potentially, the development of mucus plugging of the airways. Summary: Excess mucus production can be targeted via therapies that focus on inhibition mucin synthesis, via reducing expression of mucin (MUC) genes, and/or inhibition of mucin secretion into the airways. Key Messages: This review discusses a number of therapeutic approaches to reduce airway mucus in asthma and COPD, including the use of synthetic and natural products. In particular, it highlights areas where clinical trials of inhibitors of particular target molecules are lacking. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are an example of a targeted therapy that has been researched to reduce mucus synthesis, as have inhibitors of EGFR's downstream signalling pathways, for example, mitogen-activated protein kinase-13 and hypoxia inducible factor-1. However, their efficacy and safety profiles are currently not up to the mark. There is clinical potential in Bio-11006, which reduces mucus secretion via the inhibition of myristoylated alanine-rich C-kinase substrate and is currently in Phase IIb trial.

100 项与 BIO-11006 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB14886

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期非小细胞肺癌	临床2期	印度	BioMarck Pharmaceuticals Ltd.	2018-02-01
非小细胞肺癌IIIB期	临床2期	印度	BioMarck Pharmaceuticals Ltd.	2018-02-01
成人呼吸窘迫综合征	临床2期	美国	BioMarck Pharmaceuticals Ltd.	2017-08-05
炎症	临床2期	美国	BioMarck Pharmaceuticals Ltd.	2008-06-01
慢性阻塞性肺疾病	临床2期	美国	BioMarck Pharmaceuticals Ltd.	2008-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03202394 (BusinessWire) 人工标引	临床2期	成人呼吸窘迫综合征	38	BIO 11006	(餘選襯齋憲遞醖選蓋憲) = no significant increase 餘觸鹽壓築選構顧淵糧 (築鑰遞膚憲壓簾繭壓簾 )	积极	2020-04-23
Biospace 人工标引	临床2期	非小细胞肺癌	60	Standard of Care+BIO 11006	(鑰構簾獵構選襯築構遞): P-Value = 0.02 更多	积极	2019-07-10
Biospace 人工标引	临床2期	非小细胞肺癌	60	Standard of Care	(鑰構簾獵構選襯築構遞): P-Value = 0.02 更多	积极	2019-07-10